DOCSLIB.ORG

Comparison of the Effect of Ciprofloxacin and Nalidixic Acid In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparison of the Effect of Ciprofloxacin and Nalidixic Acid In IJHS 2018;4(2):35-38 Archive of SID doi: 10.22100/ijhs.v4i2.597 ijhs.shmu.ac.ir Original Article IJHS International Journal of Health Studies Comparison of the Effect of Ciprofloxacin and Nalidixic Acid in the Infection of Different Parts of the Urinary Tract Ehsan Binesh1, Mehdi Mirzaii2, Fateme Asadi3, Pouneh Zolfaghari4, Nasim Nikkheslat4, Mohammad Bagher Sohrabi5 1 Department of Infectious, Imam Hossain Center for Education, Research and Treatment, Shahroud University of Medical Sciences, Shahroud, Iran. 2 Department of Microbiology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran. 3 Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran. 4 Vice-chancellery of Health, Shahroud University of Medical Sciences, Shahroud, Iran. 5 School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran. Received: 1 June 2019 Accepted: 23 June 2019 Abstract common of which is E. coli. Over 80% are caused by E- coli, a Gram negative bacillus. Other causes of urinary tract infection Background: Urinary tract infection (UTI) is one of the most common include Enterobacter agglomerans, Proteus mirabilis, Klebsiella bacterial infections. The most common cause is Escherichia coli. This pneumonia, Pseudomonas aeruginosa, Staphylococcus research is done with the aim at compare effect of ciprofloxacin with saprophyticus and Enterococcus faecalis.5-6 E. coli is a large nalidixic acid in the infection of different parts of the urinary tract. heterogeneous group of gram-negative bacilli in the form of a Methods: In this cross-sectional study, 130 patients with symptoms of bar without spores, a part of the natural flora of the intestine. the urinary tract infection referred to Imam Hossain Hospital of This bacterium is a natural habitat for humans and animals, but Shahrood were studied. For the all patients, urine samples were if it enters other devices in different ways, it will cause collected by standard method and urine analysis and culture was 7-9 performed. Then, positive culture samples were tested by antibiogram infection. Treatment for mild infections is often out-patient and the resistance rate for the two antibiotics ciprofloxacin and and with oral antibiotics but in severe cases, especially in nalidixic acid and MBC and MIC was investigated. pyelonephritis, treatment is administered as an adjunct to an 10 Results: Of the 130 patients with symptoms of UTI (fever, flank pain or antibiotic. Appropriate antibiotic selection depends on several tenderness and dysuria, urgency or frequency (84 patients had positive factors such as the outcome of urine culture and its urine culture. Of all patients with positive urine, 31 cases had antibiogram, the age of the patient and the presence of symptoms of pyelonephritis, 25 patients had symptoms of cystitis and accompanying illnesses. One of the problems of treatment is 28 patients had symptoms of UTI. In antibiogram for positive urine the antibiotic-resistant strains.11-12 This problem occurs as a samples, 21 pieces were resistant to ciprofloxacin and 46 pieces were defensive reaction by infectious agents and from the very resistant to nalidixic acid which significantly reduced resistance to beginning, the discovery of antibiotics has also existed.11 It is ciprofloxacin (P=0.005). There was no significant difference between also a matter of accelerating and intensifying the process of the two antibiotics in place of clinical symptoms and drug resistance. resistance to mankind and preventing the current self-made So there was no significant difference between the two MIC and MBC process to reduce the occurrence of resistance and control.12 in place of clinical symptoms and drug resistance. Factors such as inappropriate diagnosis of illnesses, the supply Conclusions: This study showed that ciprofloxacin is more effective in of counterfeit drugs to the pharmaceutical market, the controlling infection of different parts of the urinary tract due to less administration of inappropriate drugs, or inappropriate dosage, drug resistance. inadequate training and the problem of hospital infections all Keywords: Escherichia coli, Ciprofloxacin, Nalidixic acid, Urinary work together and increase drug resistance.13 Ciprofloxacin and tract infection. nalidixic acid are increasingly used in the treatment of urinary *Corresponding to: MB Sohrabi, Email: [email protected] tract infections but the drug resistance level is not clear.14-15 Please cite this paper as: Binesh E, Mirzaii M, Asadi F, Zolfaghari P, The procedure for performing antibiotics is based on the MIC Nikkheslat N, Sohrabi MB. Comparison of the effect of ciprofloxacin and (The lowest amount of antibiotics that can significantly inhibit nalidixic acid in the infection of different parts of the urinary tract. Int J the growth of an organism after a specific incubation period) Health Stud 2018;4(2):35-38. and MAC (The lowest concentration of antibiotics, which can reduce the bacterial population by 1000 times after 24 hours) criteria, which, according to the American National Laboratory Standards Committee (NCCLS), is a gold standard for Introduction determining antimicrobial susceptibility and resistance.16 Also, since conventional antibiogram methods based on disk have Urinary tract infections (UTI) are a generic term for the many problems (lack of reliability and more human error) and replacement and growth of a pathogen in the kidney, bladder, quality we decided to test antibiotic ciprofloxacin and nalidixic and urethra. The prevalence of urinary tract infection in boys is Acid antibodies against E. coli based on the precise MIC and more common the girls than in the first year of life, and after MBC methods.16-18 Furthermore, the resistance rates of urinary 1-2 one year, the prevalence of girls is significantly higher. The E. coli to various antimicrobials show large inter-country reason for such a distribution of age and sex can be attributed variability. Only a few studies have shown that E. coli to the shortness of the urethra in the female genome, which resistance rates differ for hospital-acquired and community- 3 makes it easier for the microbe to go into the urinary tract. The acquired UTI.9-11 Measuring and comparing the levels of AMR most important symptoms of the disease are including pain, in both hospital- and community-acquired UTI is essential hematuria, dysuria, urinary incontinence, pain in the lower because although effects of AMR are mainly felt in healthcare 3-4 back, fever and abdominal pain. Several organisms interfere facilities, the greatest use of antimicrobials occurs in the with the development of urinary tract infections, the most community.19 The prevalence of AMR including hospital and 35 | International Journal of Health Studies 2018;4(2) www.SID.ir Archive of SID Binesh et al community urinary E. coli resistance levels is not completely preparation of antibiotic stokes. After obtaining the appropriate known in Iran. Obtaining this information is important because amounts of antibiotics in milligrams, each antibiotic was it not only provides knowledge about the health status of a dissolved in its proper solvent and reached the appropriate population, but also contributes to disease management volume. Finally, of Micro Broth Dilution method was used to 13 decisions. This study was done with the aim of compare effect determine the MIC level of antibiotics. In order to determine of ciprofloxacin with nalidixic acid in the infection of different the MBC (Minimum bacterial Concentration), 10 μl of wells parts of the urinary tract. that were free from turbidity were removed and cultured on the Materials and Methods surface of the Muller Hinton Agar and after 18-24 hours incubation at 37 ° C was investigated. The amount of MBC This is a cross-sectional study with the aim of comparing was determined based on the minimum concentration of drug the effectiveness and resistance rate of two antibiotics that has a fungal effect on the bacteria. Data were analyzed ciprofloxacin and nalidixic acid on UTI. In this study, 130 using SPSS software. patients admitted to Imam Hossain Hospital of Shahroud with the diagnosis of clinical signs of UTI (upper urinary tract This study has an ethics code number including: fever, flank pain or tenderness and lower urinary (IR.SHMU.REC.1394.66) from research deputy of Shahroud tract including dysuria, urgency or frequency), during (March University of Medical Sciences. The essential information and 2015 to February 2016) were selected by convenient method. the objectives of the study were explained to the patients and The initial selection of these patients was based on the positive written consent was obtained for participation in the plan. urine culture test. Then a researcher-made questionnaire containing demographic and clinical data was completed by Results patients. Of the 130 patients with symptoms of UTI, 84 patients Inclusion criteria: having urinary tract infection (64.6%) had positive urine culture. Among the positive samples (pyelonephritis, cystitis and urethritis) and satisfaction of of urine culture, 78 cases (92.9%) were E. coli. Three cases entering the research. (3.6%) were coagulase-negative Staphylococci, two cases Exclusion criteria, if there was: a history of allergy to (2.4%) were E. agglomerans and one case (1.2%) was K. nalidixic acid; evidence of renal dysfunction (serum creatinine pneumonias. Of the 84 patients, 64 (76.2%) were female and greater than 130 μmol/L); a history of renal
Load more

Recommended publications
  • A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sebastien Lefebvre
    A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sebastien Lefebvre To cite this version: Tessa Trouchon, Sebastien Lefebvre. A Review of Enrofloxacin for Veterinary Use. Open Journal of Veterinary Medicine, 2016, 6 (2), pp.40-58. 10.4236/ojvm.2016.62006. hal-01503397 HAL Id: hal-01503397 https://hal.archives-ouvertes.fr/hal-01503397 Submitted on 7 Apr 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NoDerivatives| 4.0 International License Open Journal of Veterinary Medicine, 2016, 6, 40-58 Published Online February 2016 in SciRes. http://www.scirp.org/journal/ojvm http://dx.doi.org/10.4236/ojvm.2016.62006 A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sébastien Lefebvre USC 1233 INRA-Vetagro Sup, Veterinary School of Lyon, Marcy l’Etoile, France Received 12 January 2016; accepted 21 February 2016; published 26 February 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract This review outlines the current knowledge on the use of enrofloxacin in veterinary medicine from biochemical mechanisms to the use in the field conditions and even resistance and ecotoxic- ity.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Pharmacology-2/ Dr
    1 Pharmacology-2/ Dr. Y. Abusamra Pharmacology-2 Quinolones, trimethoprim & sulfonamides Dr. Yousef Abdel - Kareem Abusamra Faculty of Pharmacy Philadelphia University 2 3 LEARNING OUTCOMES After completing studying this chapter, the student should be able to: Classify the drugs into subgroups such as quinolones and sulfonamides. Recognize the bacterial spectrum of all these antibiotic and antibacterial groups. Summarize the most remarkable pharmacokinetic features of these drugs. Numerate the most important side effects associated with these agents. Select the antibiotic of choice to be used in certain infections, as associated with the patient status including comorbidity, the species of bacteria causing the infection and concurrently prescribed drugs. Reason some remarkable clinical considerations related to the use or contraindication or precaution of a certain drug. Illustrate the mechanism of action of each of these drugs. • Following synthesis of na lidixic a c id in the early 1960s, continued modification of the quinolone nucleus expanded the spectrum of activity, improved pharmacokinetics, and stabilized compounds against common mechanisms of resistance. • Overuse resulted in rising rates of resistance in gram-negative and gram-positive organisms, increased frequency of Clostridium difficile infections, and identification of numerous tough adverse effects. • Consequently, these agents have been relegated to second-line options for various indications. 4 Pharmacology-2/ Dr. Y. Abusamra Only will be mentioned here 5 Pharmacology-2/ Dr. Y. Abusamra Most bacterial species maintain two distinct type II topoisomerases that assist with deoxyribonucleic acid Topoisomerases: Supercoiling Unwinding (DNA) replication: . DNA gyrase {supercoiling} and . Topoisomerase IV {Unwinding}. Following cell wall entry through porin channels, fluoroquinolones bind to these enzymes and interfere with DNA ligation.
    [Show full text]
  • Download Full Article As
    Article Comparative screening of dose-dependent and strain- specific antimicrobial efficacy of berberine against a representative library of broad-spectrum antibiotics Stephanie Sun1, Andrew Su2, Simrun Sakhrani3, Bhavesh Ashok4, Sarah Su5, Sarada Rajamanickam4, and Edward Njoo6 1BASIS Independent Silicon Valley, San Jose, CA; 2Foothill High School, Pleasanton, CA; 3The College Preparatory School, Oakland, CA; 4Amador Valley High School, Pleasanton, CA; 5Los Altos High School, Los Altos, CA; 6Department of Chemistry, Biochemistry, & Physical Science, Aspiring Scholars Directed Research Program, Fremont, CA SUMMARY methodology behind systematic screening of drugs while Widespread use of antibiotics has resulted in the trying to find a drug to treat syphilis in 1904, and Flemming, emergence of antibiotic-resistant bacteria strains, who accidentally discovered penicillin in 1929. Since then, increasing the necessity in research towards the hundreds of antimicrobial agents have been developed and identification of novel antibiotic agents. Berberine, clinically screened, the majority of which are derived from a natural alkaloid that is extracted from the roots natural products (3). Current antibiotics lack diversity in and stems of plants in the genus Berberis, has been their targets, with almost all antibiotics inhibiting DNA, RNA, documented to have medicinal potential since 3000 protein synthesis, or cell wall synthesis. In fact, around half of BC, where it was used as an antibacterial agent in all antibiotics target the cell wall. Antibiotics also lack diversity ancient Chinese medicine. Since then, berberine and in scaffold design - the core structure of small molecules- with synthesized analogs have been studied for a wide most of the novel antibiotics within the past forty years coming range of medicinal properties, including antimicrobial activity.
    [Show full text]
  • Challenges of Antibacterial Discovery Lynn L
    CLINICAL MICROBIOLOGY REVIEWS, Jan. 2011, p. 71–109 Vol. 24, No. 1 0893-8512/11/$12.00 doi:10.1128/CMR.00030-10 Copyright © 2011, American Society for Microbiology. All Rights Reserved. Challenges of Antibacterial Discovery Lynn L. Silver* LL Silver Consulting, LLC, 955 S. Springfield Ave., Unit C403, Springfield, New Jersey 07081 INTRODUCTION .........................................................................................................................................................72 The Discovery Void...................................................................................................................................................72 Class Modifications versus Novel Classes.............................................................................................................72 BACKGROUND............................................................................................................................................................72 Early Screening—a Brief and Biased Philosophical History .............................................................................72 The Rate-Limiting Steps of Antibacterial Discovery ...........................................................................................74 The Multitarget Hypothesis ....................................................................................................................................74 ANTIBACTERIAL RESISTANCE ..............................................................................................................................75
    [Show full text]
  • Disabling and Potentially Permanent Side Effects Lead to Suspension Or Restrictions of Quinolone and Fluoroquinolone Antibiotics
    11 March 2019 EMA/175398/2019 Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics On 15 November 2018, EMA finalised a review of serious, disabling and potentially permanent side effects with quinolone and fluoroquinolone antibiotics given by mouth, injection or inhalation. The review incorporated the views of patients, healthcare professionals and academics presented at EMA’s public hearing on fluoroquinolone and quinolone antibiotics in June 2018. EMA’s human medicines committee (CHMP) endorsed the recommendations of EMA’s safety committee (PRAC) and concluded that the marketing authorisation of medicines containing cinoxacin, flumequine, nalidixic acid, and pipemidic acid should be suspended. The CHMP confirmed that the use of the remaining fluoroquinolone antibiotics should be restricted. In addition, the prescribing information for healthcare professionals and information for patients will describe the disabling and potentially permanent side effects and advise patients to stop treatment with a fluoroquinolone antibiotic at the first sign of a side effect involving muscles, tendons or joints and the nervous system. Restrictions on the use of fluoroquinolone antibiotics will mean that they should not be used: to treat infections that might get better without treatment or are not severe (such as throat infections); to treat non-bacterial infections, e.g. non-bacterial (chronic) prostatitis; for preventing traveller’s diarrhoea or recurring lower urinary tract infections (urine infections that do not extend beyond the bladder); to treat mild or moderate bacterial infections unless other antibacterial medicines commonly recommended for these infections cannot be used. Importantly, fluoroquinolones should generally be avoided in patients who have previously had serious side effects with a fluoroquinolone or quinolone antibiotic.
    [Show full text]
  • In Silico Studies of Inhibitors of Dihydrofolate Reductase And
    Archana Moon*et al. /International Journal of Pharmacy & Technology ISSN: 0975-766X CODEN: IJPTFI Available Online through Research Article www.ijptonline.com IN SILICO STUDIES OF INHIBITORS OF DIHYDROFOLATE REDUCTASE AND DIHYDROPTEROATE SYNTHASE OF E.COLI Archana Moon1, Deeba Khan2, Pranjali Gajbhiye3 & Monali Jariya4 1,2,3&4 University Department of Biochemistry, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur -440033. Email: [email protected] Received on: 10-02-2017 Accepted on: 22-03-2017 Abstract: In the past two decades, antibiotic resistance has become an increasingly severe health problem. Bacterial infections caused by resistant strains are problematic in numerous hospitals around the world, especially in patients compromised by age, illness, and treated with immune-suppressant drugs. Antibiotics have a distinct mechanism of action capable of modifying microbial metabolism and physiological processes such as translation, DNA replication and cell wall biosynthesis. In this context, it is essential to increase the understanding of resistance mechanisms in order to develop drugs with potential activity against these pathogens. Escherichia coli is the most common causative agent of urinary tract infection (UTI), and diagnosing this infection usually relies on bacteriologic methods. Urinary tract infection (UTI) is the second most common bacterial infection after respiratory tract infection. Approximately 75-95% of UTIs are caused by Escherichia coli. Sulfonamides are competitive inhibitors of dihydropteroate synthase, the bacterial enzyme responsible for the incorporation of para-aminobenzoic acid (PABA) into dihydropteroic acid, the immediate precursor of folic acid. Trimethoprim exerts a synergistic effect with sulfonamides. It is a potent and selective competitive inhibitor of microbial dihydrofolate reductase, the enzyme that reduces dihydrofolate to tetrahydrofolate.
    [Show full text]
  • Pharmacogenomic Associations Tables
    Pharmacogenomic Associations Tables Disclaimer: This is educational material intended for health care professionals. This list is not comprehensive for all of the drugs in the pharmacopeia but focuses on commonly used drugs with high levels of evidence that the CYPs (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5 only) and other select genes are relevant to a given drug’s metabolism. If a drug is not listed, there is not enough evidence for inclusion at this time. Other CYPs and other genes not described here may also be relevant but are out of scope for this document. This educational material is not intended to supersede the care provider’s experience and knowledge of her or his patient to establish a diagnosis or a treatment plan. All medications require careful clinical monitoring regardless of the information presented here. Table of Contents Table 1: Substrates of Cytochrome P450 (CYP) Enzymes Table 2: Inhibitors of Cytochrome P450 (CYP) Enzymes Table 3: Inducers of Cytochrome P450 (CYP) Enzymes Table 4: Alternate drugs NOT metabolized by CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 or CYP3A5 enzymes Table 5: Glucose-6-Phosphate Dehydrogenase (G6PD) Associated Drugs and Compounds Table 6: Additional Pharmacogenomic Genes & Associated Drugs Table 1: Substrates of Cytochrome P450 (CYP) Enzymes Allergy Labetalol CYP2C19 Immunosuppressives Loratadine CYP3A4 Lidocaine CYP1A2 CYP2D6 Cyclosporine CYP3A4/5 Analgesic/Anesthesiology CYP3A4/5 Sirolimus CYP3A4/5 Losartan CYP2C9 CYP3A4/5 Codeine CYP2D6 activates Tacrolimus CYP3A4/5 Lovastatin
    [Show full text]
  • Fluoroquinolone Use in Paediatrics: Focus on Safety and Place in Therapy
    18th Expert Committee on the Selection and Use of Essential Medicines (2011) Fluoroquinolone Use in Paediatrics: Focus on Safety and Place in Therapy Jennifer A. Goldman, M.D. 1,2, Gregory L. Kearns, Pharm.D., Ph.D. 1,3,4 Departments of Pediatrics 1 and Pharmacology 3, University of Missouri – Kansas City and the Divisions of Pediatric Infectious Disease 2 and Clinical Pharmacology and Medical Toxicology, 4 Children’s Mercy Hospital, Kansas City, MO, USA Commissioned work for the Guidelines Group for the Revision of the “Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children”, World Health Organization, 30-31 March 2010, Geneva, Switzerland 1 I. Introduction The first quinolone, nalidixic acid, was developed in the 1960s and was used (off- label) in pediatric therapeutics without restriction. Consequent to their broad spectrum of antimicrobial (including anti-mycobacterial) effect and perceived excellent safety profile, there was considerable hope and expectation that this class of antibiotics would find an important place in pediatric therapeutics. However, reports of quinolone-associated injury in weight bearing joints of juvenile animals resulted not only in an apparent contraindication to their use in human infants and children but also, completely derailed their formal development by pharmaceutical companies for use in pediatrics. While this situation resulted from a genuine concern for safety seemingly supported by relevant experimental findings, it served initially to remove a potentially useful
    [Show full text]
  • A Review of Enrofloxacin for Veterinary Use
    Open Journal of Veterinary Medicine, 2016, 6, 40-58 Published Online February 2016 in SciRes. http://www.scirp.org/journal/ojvm http://dx.doi.org/10.4236/ojvm.2016.62006 A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sébastien Lefebvre USC 1233 INRA-Vetagro Sup, Veterinary School of Lyon, Marcy l’Etoile, France Received 12 January 2016; accepted 21 February 2016; published 26 February 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract This review outlines the current knowledge on the use of enrofloxacin in veterinary medicine from biochemical mechanisms to the use in the field conditions and even resistance and ecotoxic- ity. The basics of biochemistry, the mechanisms of action and resistance and pharmacokinetics are presented. Then an overview of available veterinary products, their efficacy and their toxicity against target species, human and environment is provided. Keywords Enrofloxacin, Antibiotic Resistances, Veterinary 1. Introduction Enrofloxacin (Figure 1(c)), or 1-Cyclopropyl-6-fluoro-7-(4-ethyl-1-piperazinyl)-1,4-dihydro-4-oxo-3-quinoli- necarboxylic acid, belongs to fluoroquinolone family which is a subfamily of quinolone. The first quinolone is the Nalidixic acid (Figure 1(a)) used in animal at the beginning of 1980s, enrofloxacin is the first fluoroquino- lone patented in 1984 [1]. The huge evolution in the quinolone family is the addition of a fluor atom on the 6th position which improves quinolones’ antibacterial spectrum [2] and creates the fluoroquinolone subfamily. Quinolones have an action on bacterial topoisomerase.
    [Show full text]
  • Mutations That Increase Expression of the Emrab-Tolc Efflux Pump Confer
    J Antimicrob Chemother 2020; 75: 300–308 doi:10.1093/jac/dkz434 Advance Access publication 21 October 2019 Mutations that increase expression of the EmrAB-TolC efflux pump confer increased resistance to nitroxoline in Escherichia coli Downloaded from https://academic.oup.com/jac/article-abstract/75/2/300/5601609 by Uppsala Universitetsbibliotek user on 01 April 2020 Fabiola Pue´rtolas-Balint1, Omar Warsi1, Marius Linkevicius1,2, Po-Cheng Tang 1,3 and Dan I. Andersson1* 1Department of Medical Biochemistry and Microbiology, Uppsala University, SE-75123, Uppsala, Sweden; 2Department of Public Health Solutions, National Institute for Health and Welfare (THL), Helsinki, Finland; 3Department of Medical Cell Biology, Uppsala University, SE-75123, Uppsala, Sweden *Corresponding author. E-mail: [email protected] Received 10 June 2019; returned 17 July 2019; revised 2 September 2019; accepted 19 September 2019 Objectives: To determine the mechanism of resistance to the antibiotic nitroxoline in Escherichia coli. Methods: Spontaneous nitroxoline-resistant mutants were selected at different concentrations of nitroxoline. WGS and strain reconstruction were used to define the genetic basis for the resistance. The mechanistic basis of resistance was determined by quantitative PCR (qPCR) and by overexpression of target genes. Fitness costs of the resistance mutations and cross-resistance to other antibiotics were also determined. Results: Mutations in the transcriptional repressor emrR conferred low-level resistance to nitroxoline [nitroxoline MIC (MICNOX)=16 mg/L] by increasing the expression of the emrA and emrB genes of the EmrAB-TolC efflux pump. These resistant mutants showed no fitness reduction and displayed cross-resistance to nalidixic acid. Second-step mutants with higher-level resistance (MICNOX=32–64 mg/L) had mutations in the emrR gene, to- gether with either a 50 kb amplification, a mutation in the gene marA,oranISupstreamofthelon gene.
    [Show full text]
  • Critically Important Antimicrobials for Human Medicine – 5Th Revision. Geneva
    WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) Critically Important Antimicrobials for Human Medicine 5th Revision 2016 Ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use Critically important antimicrobials for human medicine – 5th rev. ISBN 978-92-4-151222-0 © World Health Organization 2017, Updated in June 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/ igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Critically important antimicrobials for human medicine – 5th rev. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]